Alzheimer’s Association Statement on Lecanemab Phase 3 Topline Data Release

CHICAGO, Sept. 27, 2022 /PRNewswire/ — On behalf of the more than 6 million Americans living with Alzheimer’s disease and their families, the Alzheimer’s Association enthusiastically welcomes the positive topline data reported today by Eisai and Biogen on the CLARITY AD global Phase 3…

Click here to view original post